America’s market-based system incentivizes medical innovation while keeping most prescriptions affordable. To benefit consumers: end foreign freeloading on US R&D, rein in PBMs & 340B, and expand DTC options. Read more: @Gingrich360 @Comm4Prosperity https://t.co/ewEZV6sCPQ